TENX - Tenax Therapeutics Inc logo

TENX

Tenax Therapeutics Inc

Tenax Therapeutics develops cardiopulmonary therapies in the U.S., focusing on treatments for pulmonary hypertension and heart failure. Its pipeline includes TNX-101, TNX-102, and TNX-201, aimed at addressing serious cardiovascular and oncological conditions.

โš•๏ธ Healthcare NASDAQ Listed 1997 $ USD
$1,000 invested 30 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth-10.09%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-78.32%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-31.83%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency
20 Years
Score1.3
Net Growth-15x
Net Trend30%
Net Income Consistency
Rev Growth100.00%
Rev Trend17%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-22x
Net Trend29%
Net Income Consistency
Rev Growthโ€”
Rev Trend14%
Revenue Consistency

See the full market ranking โ†’

Tenax Therapeutics Inc fundamental performance

Between 2005 and 2025, revenue went from -$ 25.63K to $ 0.00 and net income went from -$ 2M to -$ 52M. Revenue increased in 3 of those 20 years; net income in 6.

Tenax Therapeutics Inc currently holds a 20-year HDB Score of 1.3 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.72โ€”
1 Year2025-08-12
$ 5.89-70.80%
5 Years2021-08-12
$ 2.48K-99.93%
10 Years2016-08-12
$ 76.16K-100.00%
20 Years2006-08-11
$ 1000K-100.00%
30 Years1996-08-12
$ 1000K-100.00%
All Time1997-01-02
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 57M$ 118M
2025$ 0.00-$ 52M$ 97M
2024$ 0.00-$ 17M$ 94M
2023$ 0.00-$ 7M$ 9M
2022$ 0.00-$ 11M$ 2M
2021$ 0.00-$ 32M$ 5M
2020$ 0.00-$ 9M$ 6M
2019$ 0.00-$ 8M$ 5M
2018$ 0.00-$ 6M$ 12M
2017$ 0.00-$ 8M$ 7M
2016$ 0.00-$ 43M$ 13M
2015$ 49.29K-$ 14M$ 20M
2014$ 49.29K-$ 14M$ 58M
2013$ 288.73K-$ 19M$ 58M
2012$ 288.73K-$ 19M$ 6M
2011$ 415.03K-$ 15M$ 3M
2010$ 322.35K-$ 10M$ 632.71K
2009$ 47.39K-$ 10M$ 2M
2008-$ 6M$ 4M
2007-$ 24.13K-$ 3M$ 940.24K
2006-$ 25.63K-$ 3M$ 382.00
2005-$ 25.63K-$ 2M$ 588.76K
2004-$ 2M$ 1M
2003-$ 2M$ 722.54K
2002-$ 3M$ 524.43K
2001$ 1.00-$ 1M$ 2M
2000$ 1.00-$ 1M$ 5M
1999$ 1.00-$ 911.34K$ 200K
1998$ 1.00-$ 800K$ 740.22K
IPO1997-$ 1M$ 53.86K
1996-$ 2M$ 76.31K
1995-$ 2M$ 76.31K

Explore beyond TENX

You're looking at Tenax Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies